Hepatitis C virus NS3 protease inhibitors
View Patent ↗The present invention relates to macrocyclic compounds of Formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
1. A compound, or a pharmaceutically acceptable salt, solvate or hydrate thereof, selected from the group consisting of:
2. The compound according to claim 1 , or a pharmaceutically acceptable salt, solvate or hydrate thereof, selected from the group consisting of:
3. A pharmaceutical composition comprising an effective amount of a compound according claim 1 , and a pharmaceutically acceptable carrier.
4. The pharmaceutical composition according to claim 3 , further comprising at least one additional therapeutic agent independently selected from the group consisting of a HCV antiviral agent, an immunomodulator, and an anti-infective agent.
5. The pharmaceutical composition according to claim 4 , wherein the HCV antiviral agent is an antiviral selected from the group consisting of a HCV protease inhibitor and a HCV NS5B polymerase inhibitor.
6. A method of treating infection by HCV in a subject in need thereof, said method comprising administering to the subject an effective amount of a compound according to claim 1 .